Mavacamten-A Targeted Therapy for Hypertrophic Cardiomyopathy.
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
received:
18
10
2022
accepted:
13
02
2023
medline:
8
5
2023
pubmed:
7
3
2023
entrez:
6
3
2023
Statut:
epublish
Résumé
The pathophysiology of hypertrophic cardiomyopathy is primarily comprised of dynamic left ventricular outflow tract obstruction, mitral regurgitation, and diastolic dysfunction. Symptoms such as dyspnea, angina, or syncope can occur because of left ventricular (LV) hypertrophy and reduced LV cavity size. Currently, focus on symptom relief through optimizing LV preload and reducing inotropy is the mainstay of therapy through the use of β-blockers, nondihydropyridine calcium channel blockers, and disopyramide. Mavacamten is a novel cardiac myosin inhibitor recently approved by the Food and Drug Administration for the treatment of obstructive hypertrophic cardiomyopathy. Mavacamten normalizes myosin and actin cross-bridging to decrease contractility and ultimately reduce LV outflow tract gradients to maximize cardiac output. In this review, we report on the mechanism of action of mavacamten, safety profile, and phase 2 and 3 clinical trial data. Because of the risk of heart failure resulting from systolic dysfunction, careful patient selection and close monitoring are key for implementing this therapy into cardiovascular practice.
Identifiants
pubmed: 36878205
doi: 10.1097/FJC.0000000000001416
pii: 00005344-202305000-00001
doi:
Substances chimiques
MYK-461
0
Benzylamines
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
317-326Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–1254
Wells S, Rowin EJ, Bhatt V, et al. Association between race and clinical profile of patients referred for hypertrophic cardiomyopathy. Circulation. 2018;137:1973–1975.
Ommen SR, Mital S, Burke MA, et al. AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American heart association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76:e159–e240.
Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:655–668.
Dybro AM, Rasmussen TB, Nielsen RR, et al. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78:2505–2517.
Kawas RF, Anderson RL, Ingle SRB, et al. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017;292:16571–16577.
Grillo MP, Erve JCL, Dick R, et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica. 2019;49():718–733.
Camzyos. Package Insert. Princeton, NJ: Bristol-Myers Squibb Company, MyoKardia Inc; 2022.
Spudich JA. Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Pflügers Arch – Eur J Physiol. 2019;471:701–717.
Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci. 2018;115:E8143–E8152.
Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med. 2019;170:741–748.
Heitner SB, Jacoby D, Lester SJ, et al. Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy patients, PIONEER-open label extension study (PIONEER-OLE). J Am Coll Cardiol. 2019;73:951.
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER (PIONEER-OLE). ClinicalTrials.gov identifier: NCT03496168.2018. https://clinicaltrials.gov/ct2/show/NCT03496168 . Accessed October 16, 2022.
Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardioly. 2020;75:2649–2660.
Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759–769.
Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80:95–108.
Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American heart association Task Force on practice guidelines. Circulation. 2011;124:e783–e831.
MyoKardia (Bristol Myers Squibb). Camzyos (Mavacamten) Risk Evaluation and Mitigation Strategy Website. 2022. https://www.camzyosrems.com/ . Accessed October 17, 2022.
A Prospective Registry Study to Assess Real-World Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM) (DISCOVER-HCM). ClinicalTrials.gov identifier: NCT05489705. 2022. https://clinicaltrials.gov/ct2/show/NCT05489705 . Accessed October 16, 2022.
U.S. Food and Drug Administration (FDA). Accepts Supplemental New Drug Application for CAMZYOS® (Mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy. Bristol Myers Squibb, 2022, https://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-FDA-Accepts-Supplemental-New-Drug-Application-for-CAMZYOS-mavacamten-in-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-to-Reduce-the-Need-for-Septal-Reduction-Therapy/default.aspx
Masri A, Olivotto I. Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter. J Am Heart Assoc. 2022;11:e024656.
Maron MS, Masri A, Choudhury L, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81:34–45.
A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy. ClinicalTrials.gov identifier: NCT05414175. 2022. https://clinicaltrials.gov/ct2/show/NCT05414175 . Accessed October 16, 2022.
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM. ClinicalTrials.gov identifier: NCT05174416. Updated January 19, 2022. 2021. https://clinicaltrials.gov/ct2/show/NCT05174416
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM. ClinicalTrials.gov identifier: NCT03723655. 2018. https://clinicaltrials.gov/ct2/show/NCT03723655 . Accessed October 16, 2022.
A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT (EMBARK-HFpEF). ClinicalTrials.gov identifier: NCT04766892. 2021. https://clinicaltrials.gov/ct2/show/NCT04766892 . Accessed October 16, 2022.
Mavacamten. Lexi-Drugs. Lexicomp. Riverwoods, IL: Wolters Kluwer Health, Inc. 2022. http://online.lexi.com . Accessed October 1, 2022.